





The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Assets, Current, reducing the Economic Capital Ratio by 8.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 289%, being 242% points above the market average of 47%.

| <b>Input Variable</b>                          | <b>Value in<br/>1000 USD</b> |
|--|------------------------------|
| Assets, Current                                | 2,839,568                    |
| Cost of Goods Sold                             | 0                            |
| Intangible Assets                              | 3,153,354                    |
| Liabilities, Current                           | 653,745                      |
| Liabilities, Non-Current                       | 0                            |
| Other Assets                                   | 415,044                      |
| Other Compr. Net Income                        | 89,041                       |
| Other Expenses                                 | 578,153                      |
| Other Liabilities                              | 0                            |
| Other Net Income                               | -105,940                     |
| Other Revenues                                 | 2,363,567                    |
| Property and Equipment                         | 127,935                      |
| Research and Development                       | 586,625                      |
| Selling, General and Administrative<br>Expense | 854,233                      |

| <b>Output Variable</b>   | <b>Value in<br/>1000 USD</b> |
|--------------------------|------------------------------|
| Assets                   | 6,535,901                    |
| Liabilities              | 653,745                      |
| Expenses                 | 2,019,011                    |
| Revenues                 | 2,363,567                    |
| Stockholders Equity      | 5,882,156                    |
| Net Income               | 238,616                      |
| Comprehensive Net Income | 283,136                      |
| Economic Capital Ratio   | 289%                         |